Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride
|ClinicalTrials.gov Identifier: NCT01123460|
Recruitment Status : Completed
First Posted : May 14, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of blood in the laboratory from patients receiving erlotinib hydrochloride may help doctors learn more about the effects of erlotinib hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers predicting response in patients with non-small cell lung cancer previously treated with erlotinib hydrochloride.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Other: enzyme-linked immunosorbent assay Other: laboratory biomarker analysis|
- To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can be utilized as biomarkers to predict response in patients with non-small cell lung cancer treated with erlotinib hydrochloride.
OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by ELISA and Luminex assays.
|Study Type :||Observational|
|Actual Enrollment :||127 participants|
|Official Title:||Measurement of Potential Biomarkers Predicting Erlotinib Response|
|Actual Study Start Date :||April 12, 2010|
|Actual Primary Completion Date :||June 12, 2010|
|Actual Study Completion Date :||June 12, 2010|
- Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01123460
|Principal Investigator:||Steven M. Dubinett, MD||Jonsson Comprehensive Cancer Center|